SCHEMBL4154636

SCHEMBL4154636

CC(O)(O)NCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.50
THRB P10828 1/20 0.50
MAPT P10636 3/20 0.48
CYP3A4 P08684 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
RIPK1 Q13546 1/20 0.47
ATM Q13315 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 2/20 0.45
ALOX12 P18054 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 2/20 0.44
LMNA P02545 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5431000 0.86 IDO1 (0.50) IDO1THRBMAPTCYP3A4KDM4E
SCHEMBL10703980 0.83 RAB9A (0.50) IDO1THRBMAPTCYP3A4KDM4E
SCHEMBL10949413 0.83 SLC6A2 (0.48) IDO1THRBMAPTCYP3A4KDM4E
SCHEMBL9482260 0.81 IDO1 (0.61) IDO1THRBMAPTCYP3A4KDM4E
SCHEMBL125129 0.81 CYP3A4 (0.52) IDO1THRBMAPTCYP3A4KDM4E
SCHEMBL1847644 0.81 RIPK1 (0.51) IDO1THRBMAPTCYP3A4KDM4E
SCHEMBL9302997 0.79 RIPK1 (0.50) IDO1THRBMAPTMEN1KMT2A
SCHEMBL22195174 0.79 RIPK1 (0.50) IDO1THRBMAPTMEN1KMT2A
Bromide SCHEMBL11038149 0.79 CYP3A4 (0.50) IDO1THRBMAPTCYP3A4KDM4E
SCHEMBL14145021 0.79 CYP3A4 (0.50) IDO1THRBMAPTCYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227540-A1 TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES TAPUAE PARTNERSHIP (NZ) 2009-09-10 US claimed
EP-1965958-A1 TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES Tapuae Partnership (NZ) 2008-09-10 EP claimed
WO-2007064236-A1 TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES TAPUAE PARTNERSHIP (NZ) 2007-06-07 WO claimed
US-20090227540-A1 TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES TAPUAE PARTNERSHIP (NZ) 2009-09-10 US disclosed
EP-1965958-A1 TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES Tapuae Partnership (NZ) 2008-09-10 EP disclosed
WO-2007064236-A1 TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES TAPUAE PARTNERSHIP (NZ) 2007-06-07 WO disclosed
JP-2000191479-A COMPOSITION FOR OXIDATION DYEING OF KERATIN FIBER AND DYEING METHOD USING THE COMPOSITION L'OREAL SA 2000-07-11 JP disclosed
US-5635467-A COMPRISING SILICA BARRIER PARTICLES; CLEANING COMPOUND AMWAY CORPORATION (US) 1997-06-03 US disclosed
US-5496486-A BLENDING WITH SILICA BARRIER PARTICLES AMWAY CORPORATION (US) 1996-03-05 US disclosed
EP-0690123-A2 Process for increasing liquid surfactant loading in free flowing powder detergents Amway Corporation (US) 1996-01-03 EP disclosed
US-4347168-A ANIONIC, ALKOXYLATED NONIONIC AND QUATERNARY AMMONIUM CATIONIC SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 1982-08-31 US disclosed
EP-0002084-A1 Granular detergent compositions for improved greasy soil removal THE PROCTER & GAMBLE COMPANY (US) 1979-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227540-A1 TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES BLVRB, BCHE, MGAM IDO1 2217/4885THRB 2465/4885MAPT 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.